Institute of Experimental Medicine CAS

Published 12. 05. 2021

An invention concerning the synthesis and use of polysubstituted pyrimidines, developed by scientists from the IOCB and IEM CAS, has already won two foreign patents this year, in Japan and Australia.

These pyrimidine derivatives are non-toxic inhibitors of prostaglandin E2 (PGE2) production; they can be considered as suitable substances for the development of new drugs useful in the treatment of diseases that are induced, or whose severity is potentiated by PGE2 overproduction. They are mainly intended for the treatment of inflammatory and cancerous diseases. They can also be used as anti-angiogenic, immunomodulatory, antiproliferative or antitumor drugs.

The patented solution is the result of cooperation between teams led by Zlatko Janeba from IOCB CAS and Zdeněk Zídek from IEM CAS. The patent is valid for 20 years from the filing date, ie until May 23, 2038.